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Background: Asian countries including Korea face aging populations and lack well-designed social
welfare systems for the elderly. The objective of this study was to compare the out-of-pocket (OOP)
medication expenditure burden of elderly and nonelderly patients with chronic conditions and to
identify those vulnerable to expenditure burden.
Methods: We analyzed data from the Korea Health Panel. We examined annual OOP medication ex-
penditures in 2008, ﬁnancial burden of OOP medication expenditures, and subjective feelings regarding
the expenditure burden of elderly and nonelderly people. We conducted descriptive analyses and
multiple regression analyses for those variables.
Results: One in 10 elderly people taking drugs for chronic conditions spent more than 10% of their in-
come on medication, and the probability of having an expenditure burden among elderly persons was 3.8
times as high as that among the nonelderly. The low-income status of elderly Koreans, combined with
the coinsurance payment policy, may result in a large medication cost burden.
Conclusion: Compared to nonelderly people in Korea, the elderly had greater OOP medication expen-
ditures and were more vulnerable to OOP medication expenditure burden. In countries where social
security systems are not sufﬁciently developed, payment policies for pharmaceuticals that consider the
income status of the poor elderly need to be implemented.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
An increase in chronic conditions associated with the aging of
the population has been observed in many countries. Chronic dis-
ease epidemics go hand in hand with increases in medication use,
and medication expenditures have been rising faster for several
years.1 Due to of budgetary pressures on pharmaceutical expendi-
tures, many countries have made patients contribute more from
their own pockets toward medication expenses.1,2
Many elderly people use prescription drugs to control chronic
conditions. Out-of-pocket (OOP) medication costs for chronic
conditions are burdensome because chronic conditions such as
hypertension or diabetes require lifelong medication.3 Previous
studies in Western countries have reported the OOP medicationre that they have no conﬂicts
ro 370, Sejong, South Korea.
tric Emergency & Critical Care Meexpense burden for elderly people.4 As a result of those studies,
charges for prescription medicines have been waived or reduced
according to age or income status in some countries.5 The economic
burden for OOPmedication costs has been pointed out as a cause of
inadequate medication use.2 Briesacher et al6 systemically
reviewed the literature and concluded that medication non-
adherence was associated with ﬁnancial burden. Thus, it is
important to identify patients who are vulnerable to OOP spending
on medications.
In South Korea, life expectancy has increased substantially from
71 years in 1990 to 80 years in 2008.7 The annual rate of increase in
pharmaceutical expenditure was greater than 10% for the past
decade.8 Pharmaceutical expenditures are covered under the Na-
tional Health Insurance or Medical Aid schemes in South Korea.
Beneﬁciaries of Medical Aid, who are primarily below the poverty
level, pay very little money for prescribed medicines. However,
cost-sharing requirements from coinsurance payments in the Na-
tional Health Insurance scheme are now substantial.dicine. Published by Elsevier Taiwan LLC. All rights reserved.
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tries, the system in South Korea is inadequate for elderly people.9
For example, South Korea's public pension system was only
introduced in 1988, and most elderly people do not beneﬁt from
it.10 The elderly are especially vulnerable to low income after
retirement; Korea's old-age poverty rate was 45% in the mid-
2000s, whereas the average rate in Organization of Economic
Cooperation and Development countries was 13.3%.10 Although
Asian countries are confronting aging populations and lack well-
designed social welfare systems for the elderly, little is known
about the medication expenditure burden among elderly Asian
men and women.
The objective of this study was to compare the OOP medication
expenditure burden among elderly and nonelderly patients with
chronic conditions, and to identify those vulnerable to medication
expenditure burden. We analyzed Korea Health Panel (KHP) data,
which represent the entire population of the country and provide
reliable data for OOP medication expenditures and household
income.2. Participants and methods
2.1. Data and study population
Data were obtained from the 2008 ﬁrst-wave survey (baseline
survey), 2008 second-wave survey, and 2009 third-wave survey of
the KHP. The KHP sampled community-dwelling households
nationwide using a multistage area probability sampling method.
The KHP database contains medical expenditure data for a na-
tionally representative sample of 21,787 noninstitutionalized in-
dividuals. Participants of the survey had been informed of the
purposes and contents of the KHP and had given consent to
participate in the survey inwritten form. The ﬁrst-wave survey was
conducted from April to October in 2008, second-wave survey from
November 2008 to April 2009, and the third-wave survey fromMay
to October 2009. The method for the ﬁrst-, second- and third-wave
surveys was similar, and the medication expenditure data were
extracted from the three surveys from January to December 2008.
KHP data were provided to researchers in deidentiﬁed form.
The study population consisted of adults aged 20 years and
older who reported having chronic conditions for which they were
taking medications. Among 12,811 people 20e64 years, 3714
(29.0%) reported using medication for chronic conditions, and
among 3029 people 65 years and older, 2165 (71.5%) did. We
excluded 239 people (4.1%) withmissing values for OOPmedication
expenditures or explanatory variables. The ﬁnal sample consisted
of 3568 nonelderly (younger than 65 years) and 2072 elderly
people (65 years and older).2.2. Measures
2.2.1. Outpatient OOP medication expenditures and burden
In the KHP survey, data on healthcare utilization and pre-
scriptions ﬁlled were collected visit by visit using a diary. Outpa-
tient OOP medication expenditures were self-reported for each
outpatient prescription. To examine exact expenditures, partici-
pants were asked to keep receipts and prescriptions. OOP medi-
cation costs included copayments for reimbursed medications and
self-payments for prescription drugs not reimbursed by National
Health Insurance or Medical Aid. The total OOP medication ex-
penditures for all prescriptions were calculated by summing the
expenditures per prescription during the January to December
2008 period and then converted to US dollars (US$1 ¼ 1102.05
won).Subjective feelings about OOP medication expenditure burdens
were assessed in the baseline survey by asking, “How much of a
ﬁnancial burden do you feel from your OOP spending for medica-
tion?”, with a ﬁve-point response option ranging from great to
none. If respondents answered that OOP medication expenditure
burden was great for any chronic condition, they were regarded as
feeling a medication expenditure burden.
The ﬁnancial burden of OOP medication expenditures was
measured as the ratio of OOP medication costs to individual in-
come, as deﬁned in previous studies.4,11 However, because KHP did
not provide individual income data, we used household income per
capita (i.e., the household income divided by the number of family
members in the household) instead of individual income. Thirteen
people had zero values for household income, and we used US$1 as
their income to calculate the burden from OOP medication costs.
Financial OOP prescription drug expenditure burdenwas deﬁned as
OOP medication expenditures greater than 10% of income, as in the
previous study.4
2.2.2. Multiple morbidities
High expenditure burdens for medications have been reported
by people with multiple chronic conditions.4 “Multiple morbid-
ities” is the state of having at least two simultaneously occurring
illnesses, independent of which diseases are involved.12 This was
measured in the baseline survey as the sum of the self-reported
chronic conditions for which medications were taken. We asked
respondents the names of the chronic conditions diagnosed by
their physicians and classiﬁed them using 298 classiﬁcations of
disease of the Korean Standard Classiﬁcation of Diseases and Causes
of Death (KSCD) (http://kostat.go.kr/kssc). The KSCD was based on
the 10th version of the International Statistical Classiﬁcation of
Diseases and Related Health Problems (ICD-10), and the 298 clas-
siﬁcations of disease of the KSCD provided 298 diseases categories.
For example, diabetes was the 104th disease and included E10eE14
of ICD-10. We classiﬁed morbidity into three groups: having only
one chronic condition, having two chronic conditions, and having
three or more chronic conditions. Hypertension (I10eI15) was the
most frequently reported chronic condition (21.1%), followed by
diabetes (E10eE14, 7.7%), osteoarthritis (M15eM19, 6.0%), and
gastritis/duodenitis (K29, 4.5%).
2.2.3. Education and household income
We measured education using the highest level of education
completed at the time of the baseline survey and classiﬁed edu-
cation into four groups: elementary school or less, middle school,
high school, college or more. Family income in 2008 was collected
by asking about income from various sources during the past year
in the 2009 third-wave survey of the KHP. This included wages,
salaries, self-employment income, social security, interest, and
rental income.We summed the income of each householdmember,
and divided the sum by the square root of the number of family
members. Equivalent household income was converted to US
dollars.
2.2.4. Other variables
Sex was classiﬁed as male or female. Marital status was classi-
ﬁed as married, separated, widowed, divorced, or never married.
Health insurance was assessed by asking respondents if they were
covered by National Health Insurance or Medical Aid. National
Health Insurance provides universal health insurance for the whole
population; Medical Aid provides free health insurance to the poor.
Because there was no respondent who was not covered by either,
we divided health insurance status into National Health Insurance
and Medical Aid.
E.-J. Park et al.1682.3. Statistical analyses
A descriptive analysis was performed to compare the charac-
teristics of elderly and nonelderly people. Generalized linear
models (GLMs) with logarithmic link and gamma distributionwere
used to test the differences in OOP medication expenditures be-
tween elderly and nonelderly people. The GLM allows multiplica-
tive models of gamma type for right-skewed cost data without
problems related to retransformation.13
We also analyzed OOP medication expenditure burden using bi-
nary logistic regression. Multiple morbidity, education, and income
were added sequentially in the GLMs or logistic regressionmodels to
assess whether a difference in expenditure or burden between
elderly and nonelderly people was present after controlling for
covariates. Then, we used binary logistic regression models to iden-
tify the subpopulations vulnerable to OOP medication cost burden
among elderly people. Statistical analyses were performed using the
Stata software (version 10.0; StataCorp, College Station, TX, USA). The
level of statistical signiﬁcance was set at p < 0.05, two-sided.
3. Results
3.1. Characteristics of the study population
Table 1 presents the sociodemographic characteristics and
multiple morbidity status of the study population. WomenTable 1
Descriptive analysis of study population.
Total












Separated or widowed or divorced 1116 (19.8)
Never married 281 (5.0)
Health Insurance
National Health Insurance 5195 (92.1)
Medical Aid 445 (7.9)





Elementary school or less 2233 (39.5)
Middle school 874 (15.5)
High school 1610 (28.6)
College or more 923 (16.4)
Equivalent household income
Mean ± SE (US$100) 158 ± 1.75
Yearly OOP medication expenditures (US$)





Feel OOP medication expenditure burdensome
No 4489 (79.6)
Yes 1151 (20.4)
Financial OOP medication expenditure burden
No 5316 (94.3)
Yes 324 (5.7)
OOP ¼ out-of-pocket.comprised 59% of both the nonelderly and elderly groups. Twelve
percent of the elderly and 6% of the nonelderly were entitled to
medical aid. More people 65 years of age and older had multiple
morbidities compared with nonelderly people. In fact, only 15% of
nonelderly people had three or more chronic conditions that
required medication, whereas about 39% of elderly people did. The
socioeconomic position of the elderly was much lower than the
nonelderly. The average equivalent household incomes (yearly) of
the elderly and nonelderly people were US$10,800 and US$18,800,
respectively.
3.2. Outpatient OOP medication expenditures and OOP expenditure
burden among elderly and nonelderly people
As shown in Table 1, people 65 years of age and older spentmore
on medication than younger adults. In fact, 36% of elderly and 18%
of nonelderly people spent $200 or more annually on medication.
The percentage (14%) of elderly people who spent $400 or more on
medication was more than twice that of their nonelderly counter-
parts (5%).
The OOP medication expenditure burden was much higher
among elderly people. Thirty percent of the elderly reported that
they felt OOP medication expenditures burdensome for any con-
dition and 15% of nonelderly people did. For 10% of elderly people
and 3% of the nonelderly, OOP medication costs represented 10% or
more of their individual income.Elderly people
(N ¼ 2072), n (%)
Nonelderly people






1230 (59.4) 2093 (58.7)
842 (40.6) 1475 (41.3)
1321 (63.8) 2922 (81.9)
748 (36.1) 368 (10.3)
3 (0.1) 278 (7.8)
1829 (88.3) 3366 (94.3)
243 (11.7) 202 (5.7)
667 (32.2) 2176 (61.0)
608 (29.3) 852 (23.9)
797 (38.5) 540 (15.1)
1396 (67.3) 837 (23.5)
260 (12.6) 614 (17.2)
298 (14.4) 1312 (36.8)
118 (5.7) 805 (22.5)
108 ± 2.09 188 ± 2.35
192 ± 4.49 121 ± 2.57
878 (42.4) 2155 (60.4)
453 (21.9) 777 (21.8)
456 (22.0) 450 (12.6)
285 (13.7) 186 (5.2)
1448 (69.9) 3041 (85.2)
624 (30.1) 527 (14.8)
1859 (89.7) 3457 (96.9)
213 (10.3) 111 (3.1)
Table 2
Out-of-pocket (OOP) medication expenditures and burden differences between Korean elderly and nonelderly people.
Model 1c Model 2d Model 3e
OOP medication expenditures, cost ratio (95% CI)
Nonelderly people (20e64 y) 1.00 1.00 1.00
Elderly people (65 þ y) 1.51 (1.40e1.63)* 1.18 (1.09e1.27)* 1.17 (1.08e1.26)*
Feel OOP medication expenditures burdensomea, OR (95% CI)
Nonelderly people (20e64 y) 1.00 1.00 1.00
Elderly people (65 þ y) 2.47 (2.14e2.85)* 1.82 (1.57e2.11)* 1.24 (1.05e1.45)*
Financial OOP medication expenditure burdenb, OR (95% CI)
Nonelderly people (20e64 y) 1.00 1.00 1.00
Elderly people (65 þ y) 3.82 (2.97e4.91)* 2.47 (1.90e3.20)* 0.90 (0.66e1.22)
CI ¼ conﬁdence interval; OR ¼ odds ratio.
*p < 0.05.
a “Feel OOPmedication expenditures burdensome” indicates that respondents responded that OOPmedication expenditures for any chronic condition made the burden too
heavy for household ﬁnances.
b “Financial OOP medication expenditure burden” is deﬁned as OOP medication expenditures >10% of income.
c Model 1 includes age group, sex, marital status, and health insurance status.
d Model 2 includes age group, sex, marital status, health insurance status, and multiple morbidities.
e Model 3 includes age group, sex, marital status, health insurance status, multiple morbidities, educational level, and household income.
Table 3
Risk factors for the out-of-pocket (OOP) medication expenditure burden of elderly









75 11.84 1.26 (0.87e1.81)
Sex
Female 9.02 1.00







National Health Insurance 11.54 1.00
Medical Aid 0.82 0.02 (0.01e0.09)*
Multiple morbidities (number of chronic conditions with medication)
1 3.30 1.00
2 8.72 3.49 (2.03e6.02)*
3 17.31 8.61 (5.21e14.23)*
Educational attainment
College or more 5.93 1.00
High school 13.42 1.42 (0.54e3.71)
Middle school 14.23 1.67 (0.63e4.43)





CI ¼ conﬁdence interval; OR ¼ odds ratio.
a “Financial OOP medication expenditure burden” is deﬁned as OOP medication
expenditures greater than 10% of income.
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OOP medication expenditures and expenditure burden between
elderly and nonelderly people in regression models. Elderly people
had OOP medication expenditures 1.5 times as high as those of
nonelderly people when controlling for sex, marital status, and
health insurance (Model 1). These higher expenditures among
elderly people remained statistically signiﬁcant after controlling for
multiple morbidities, education, income, and other covariates
(Model 3).
When we controlled the explanatory variables (sex, marital
status, and health insurance status), the elderly were more likely
than the nonelderly to perceive their medication expenditures as
burdensome (odds ratio, 2.47; 95% conﬁdence interval, 2.14e2.85).
Controlling for sex, marital status, and health insurance status, the
probability of having a ﬁnancial OOP medication expenditure
burden among elderly people was 3.8 times as high as that among
the nonelderly (Model 1). The difference between nonelderly and
elderly people was reduced when adjusting for multiple morbid-
ities (Model 2) and was not signiﬁcantly different (Model 3) after
controlling for education and income differences between the
groups.
3.3. Subpopulations vulnerable to OOP medication cost burden
among elderly people
Table 3 presents the logistic regression results for OOP medi-
cation cost burden among elderly people. Male sex, national health
insurance, multiple morbidity, and low income were signiﬁcantly
associated with cost burden. OOP medication cost burden was
higher for elderly people with three or more chronic conditions
compared with those with only one chronic condition (odds ratio,
8.61; 95% conﬁdence interval, 5.21e14.23), and income was a sig-
niﬁcant explanatory variable for the medication cost burden of the
elderly.
4. Discussion
Our results indicate that, compared with nonelderly people,
elderly people spent more on medication and were more vulner-
able to ﬁnancial burden because of OOP medication expenditures.
The number of elderly people who spent $200 or more and $400 or
more annually on medication was approximately 2- and 2.6-fold
greater, respectively, than their nonelderly counterparts. The cost
ratio for elderly people was signiﬁcantly higher than for the non-
elderly based on the multiple regression analysis.Owing to multiple morbidities and low-income status, elderly
people incur a higher medication cost burden than the nonelderly.
The elderly people had a disproportionately higher prevalence of
cases with three or more chronic conditions (39%), whereas the
nonelderly had a lower prevalence of such cases (15%). The mean
yearly equivalent household income of the elderly people
(US$10,800) was about 60% of the nonelderly (US$18,800).
The Korean National Health Insurance (NHI) system applies 30%
coinsurance for outpatient medication. Seniors 65 years of age and
older pay 1200 won when the prescription medication cost is less
than 10,000 won, but this is rarely the case in patients with chronic
conditions. In fact, prescriptions for which OOP expense was
reduced to 1200 won for the elderly represented only 2.4% of all
prescription costs in 2010.14 In the NHI system, lower coinsurance
E.-J. Park et al.170rates (5% or 10%) are applied to patients with severe diseases such
as cancer or orphan diseases. However, these lower rates are not
applied to patients with chronic conditions. People with income
status below the poverty level can beneﬁt from the Medical Aid
program, but people with assets or working children are excluded
from these beneﬁts.
Patients must pay the 30% coinsurance for outpatient medication
regardless of age or income status and pay OOP for uncovered
medications. Elderly patients with multiple morbid conditions are
especially vulnerable to polypharmacy and overmedication in the
fragmented healthcare system. In Korea, primary care and hospital
care are not well connected, and medical care intervention is highly
segmented by a majority of clinical specialties even in the hospital.
Patients must see different physicians to manage their multiple
medical problems, resulting in overmedication and polypharmacy.15
This could be an important reason for the high OOP medication ex-
penditures of patients with multiple morbid conditions.
Generally, seniors have limited income in retirement, but the
low-income status among the elderly is much greater in developing
countries where social security systems, including pension security,
are not sufﬁciently developed. In Korea, fewer than 30% of elderly
people are entitled to public pension beneﬁts.16 The low-income
status of elderly Koreans, combined with the coinsurance pay-
ment policy, may result in a considerable medication cost burden.
Our results raise serious concerns regarding the affordability of
prescription drugs for poor seniors in Korea. Gruber17 showed that
the average person is not inﬂuenced by coinsurance, but it can
negatively affect the health of low-income people. Wagstaff and
van Doorslaer18 demonstrated in an international study that OOP
payments were so regressive, especially in countries without ex-
emptions from charges based on poverty or without a social se-
curity system, that low income people pay proportionally more of
their income for healthcare. This was evident in Korean elderly,
who are generally poor owing to an insufﬁcient social security
system. This issue is of great concern because of Korea's rapidly
aging population and increased use of high-cost drugs.
Drug beneﬁt designs need to consider not only pharmaceutical
expenditures but also the social environment surrounding the
elderly population. Medication cost burden was reported to inﬂu-
ence medication nonadherence.6,19 Moreover, the analysis of the
Korea NHI claims database showed that low medication adherence
was associated with higher hospitalization expenditures among
patients with hypertension or diabetes.20 A drug cost assistance
program or drug beneﬁt that takes into consideration income sta-
tus may alleviate the OOP medication burden of poor elderly peo-
ple. Additionally, patients should be encouraged to discuss their
medication cost problems with their physicians.21
Promoting the use of generic medicine is a key measure to
reduce pharmaceutical costs. In Korea, the NHI covers both original
and generic medicines with identical active ingredients. Original
and generic medicines accounted for 54.8% and 41.4% of the
outpatient medication expenditures in 2011, respectively. Of the
generic medicine expenditures, more than two-thirds are from
high-cost generic medicines that cost more than 80% of the cost of
the original medicines.15 Promoting the use of low-priced generic
medicines is necessary to alleviate the medication cost burden in
Korea.
In this study, we focused on the outpatient services investi-
gating the OOP medication costs of the elderly. Elderly patients can
be hospitalized because of their medical problems; however,
separating the medication costs from the OOP hospitalization ex-
penses is not possible using the KHP data. The elderly can also be
cared for in a long-term care center where medical service is not
provided. The KHP data do not include people residing in long-term
care facilities.Several limitations need to be considered when interpreting the
results of our study. First, OOP expenditures in our study included
both 30% coinsurance payments and full payments for medications
not covered by NHI. Our data did not separate these expenses. Jang
et al22 estimated that expenditures for nonreimbursed medicines
were 5.9% of total medication expenditures. Second, based on
values in previous studies,4 a 10% pharmaceutical expenditure/in-
come ratio was used to deﬁne the ﬁnancial cost burden in this
study; however, it is possible that this indicator does not sufﬁ-
ciently reﬂect the burden of OOP spending. However, the analysis of
the subjective feeling of burden yielded a pattern of results similar
to that of ﬁnancial cost burden measured by expenditure ratio.
Third, chronic conditions diagnosed by physicians were self-
reported by respondents, and were classiﬁed using 298 classiﬁca-
tions of disease of the KSCD. Because 298 classiﬁcations of disease
did not provide detailed disease information (i.e., moderate or se-
vere liver disease), we could not calculate the morbidity index such
as Charlson comorbidity index. This may have either positively or
negatively inﬂuenced the association of multiple morbidities with
OOP medication expenditure burden in our study.
Our ﬁndings provide insight into payment policies for phar-
maceuticals in many countries that have reformed health insurance
policies, particularly in Asian countries where the aging population
is increasing rapidly and the majority of elderly people are not
entitled to pension beneﬁts. This study demonstrates that medi-
cation represents a ﬁnancial burden on elderly people with chronic
conditions. As shown by the example of Medicare Part D, drug
coverage is critical to relieving medication cost burden23; however,
the impact of cost sharing should not be neglected. Given the
economic burden from chronic conditions that require lifelong
medication, policy measures are needed to alleviate the cost
burden of the elderly with chronic conditions, such as reducing the
coinsurance on medications for chronic conditions.References
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